Testosterone Cypionate Injection-Site Pain: Alternatives Without This Side Effect

Start by identifying what actually needs to change

Depo-Testosterone is labeled for deep intramuscular injection. Its current prescribing information identifies cottonseed oil as an inactive ingredient and lists injection-site inflammation and pain among adverse reactions. It does not say that pain occurs in a fixed percentage of users, that the oil normally creates a specific immune response, or that a particular needle or warming method prevents the problem [1].

That distinction matters because several different events can look like “injection-site pain.” They include mechanical soreness, bruising, an administration problem, a localized infection, and a delayed hypersensitivity reaction. A published 2024 case report documents delayed hypersensitivity to testosterone cypionate, but one case cannot establish that most reactions are allergies or that changing carrier oil is a dependable remedy [2].

Before choosing an alternative, record the manufacturer, concentration, volume, route, site, needle and technique taught by the clinician, time to symptom onset, whether the area is improving or expanding, and whether there is warmth, drainage, rash, fever, breathing difficulty, or impaired function. That information helps the prescriber decide whether the useful change is technique training, route, formulation, or urgent evaluation.

Option 1: clinician-directed subcutaneous testosterone cypionate

Subcutaneous administration places medication in subcutaneous tissue rather than deep muscle. This can avoid the intramuscular needle path, but it does not guarantee a reaction-free site. Small nodules, tenderness, bruising, or other local effects can still occur.

The evidence is stronger than the fabricated comparisons that previously appeared on this page. A pilot crossover study evaluated pharmacokinetics, safety, and acceptability when people receiving gender-affirming testosterone used subcutaneous rather than intramuscular injection [3]. A separate cohort found subcutaneous testosterone effective and preferred by participants in that setting [4]. Another study reported stable serum testosterone concentrations between weekly subcutaneous injections [5]. These studies support a clinician-supervised option; they do not prove universal pain-score reductions, a single best needle, or a one-size-fits-all cypionate dose.

There is an important labeling boundary. Depo-Testosterone is labeled for intramuscular use, so injecting that specific product subcutaneously is an off-label route decision [1]. The prescriber should confirm that the exact formulation, dose, interval, device, and monitoring plan are appropriate. A patient should not convert an IM prescription to a subcutaneous schedule by copying numbers from another product or study.

Option 2: an FDA-approved subcutaneous testosterone product

XYOSTED is testosterone enanthate supplied in a single-dose autoinjector for subcutaneous administration in the abdominal region once weekly. Its label gives product-specific strengths, administration instructions, dose-adjustment timing, contraindications, and monitoring [6]. This can be a useful discussion when the intramuscular route itself is the main obstacle.

XYOSTED is not testosterone cypionate, and its autoinjector should not be treated as interchangeable with a vial and syringe. It can still cause injection-site reactions and retains the systemic risks and monitoring needs of testosterone therapy. The meaningful advantage is that the route and device are part of the approved product instructions, not that local discomfort is impossible.

Option 3: transdermal testosterone gel

Testosterone gel removes injections from the routine entirely. Current gel labeling describes once-daily topical use and dose adjustment based on measured testosterone concentrations [7]. For someone whose only local problem is an injection site, that route change directly removes the needle and oil depot.

The tradeoff moves to the skin and household environment. Application-site irritation can occur. More importantly, testosterone gel labeling carries a boxed warning about secondary exposure: children and other people should not contact unwashed or uncovered application sites. Hands must be washed after application, the site covered after drying, and the site washed before anticipated skin-to-skin contact [7]. Different gel concentrations also have different application sites and instructions, so directions from one product should not be applied to another.

Gel absorption and the timing of laboratory measurement are product-specific. A clinical trial of testosterone gel showed that transdermal delivery can maintain testosterone concentrations in hypogonadal men, but it does not establish that every person absorbs every gel equally [8]. Daily adherence, skin tolerance, contact precautions, and the planned blood-test timing are part of the route decision.

Option 4: Natesto nasal testosterone gel

Natesto is a metered testosterone nasal gel. The current label recommends one actuation in each nostril three times daily, separated by about six to eight hours, and directs periodic testosterone measurement beginning as soon as one month after initiation [9]. It avoids intramuscular injection and avoids a testosterone-bearing arm or shoulder application site.

The tradeoff is a nasal product used three times each day. Nasal symptoms can occur, and the label includes instructions for severe rhinitis and cautions about other intranasal medications [9]. The old version of this page claimed that Natesto preserves spermatogenesis in a defined percentage and cited a paper about ureteral-stone imaging. That claim and citation have been removed. Fertility goals require a direct discussion before testosterone therapy because exogenous testosterone can suppress spermatogenesis; a nasal route should not be presented as a fertility guarantee.

Option 5: oral testosterone undecanoate

Jatenzo is an oral testosterone undecanoate capsule taken in the morning and evening with food. Its current label specifies a starting regimen, dose adjustment based on a testosterone sample drawn at a defined time after the morning dose, and continued periodic monitoring [10]. A phase 3 trial found that most participants achieved testosterone concentrations in the study's eugonadal range after titration [11].

This route eliminates injection-site pain and the contact-transfer issue of topical gel, but it is not “testosterone without monitoring.” The label warns that Jatenzo can increase blood pressure and lists other adverse effects and laboratory considerations [10]. Food, twice-daily adherence, drug interactions, blood pressure, hematocrit, testosterone measurement, and other indicated monitoring all matter. The current label says to take it with food; it does not support the old page's universal “at least 15 grams of fat” instruction.

Option 6: testosterone pellets

Testopel consists of 75 mg testosterone pellets implanted subcutaneously by a clinician. The pellets slowly release testosterone, replacing repeated self-injections with an office procedure [12]. That may be attractive when adherence to daily or weekly treatment is difficult.

Pellets do not eliminate local procedures. Current labeling describes postmarketing implant-site infection and pellet extrusion [12]. Published studies report variable extrusion and infection rates depending on product era, operator, procedure, and follow-up; those results should not be collapsed into a universal promise [13]. Dose adjustment is also less immediate once pellets are implanted. The decision therefore trades frequent administration for a procedure, a longer dosing interval, and less short-term reversibility.

Options this page no longer recommends as evidence-backed shortcuts

Changing a compounded vial from cottonseed oil to grapeseed oil was previously presented as though a 135-person crossover study proved that 71% of users had less pain. The cited PMID resolves to unrelated research, and no verified study supporting those numbers was found. Compounded drugs are not FDA approved, and FDA explains that they do not undergo premarket review for safety, effectiveness, or quality [14]. A specific allergy or excipient concern can justify specialist and prescriber review, but an invented oil-comparison statistic cannot.

The former page also prescribed warming vials in water, icing, massage, fixed needle gauges, a Z-track sequence, fixed subcutaneous doses, and exact formulation-switch timing. The cited literature did not support those testosterone-specific instructions. Injection technique should come from the prescriber, pharmacist, product Instructions for Use, or trained clinician for the exact product. General intramuscular-injection literature can inform technique, but it cannot establish a universal testosterone protocol [15].

A practical route-comparison framework

The 2018 Endocrine Society guideline recommends choosing a formulation with attention to patient preference, pharmacokinetics, treatment burden, cost, and formulation-specific adverse effects [16]. For a pain-driven switch, the most useful questions are concrete:

1. Is the current reaction compatible with ordinary soreness, infection, or hypersensitivity?
2. Is avoiding deep intramuscular injection enough, or is avoiding every needle the priority?
3. Can the person follow a daily topical routine while preventing secondary contact?
4. Is three-times-daily nasal administration realistic?
5. Is twice-daily oral dosing with food realistic, and is blood pressure controlled?
6. Is an office implantation procedure acceptable despite infection and extrusion risk?
7. What testosterone, hematocrit, blood-pressure, prostate, and symptom monitoring is indicated for this person and product?
8. How will the prescriber transition between products without overlapping or under-treating?

There is no evidence-backed reason to preserve an intolerable injection route simply because it is familiar. There is also no route that removes all adverse effects. The best alternative is the one that addresses the verified cause of the local problem while maintaining an appropriate indication, a product-specific dose, and a monitoring plan the patient can follow.